EP300 and acute lymphoblastic leukemia: In addition to our results demonstrating that JMJD3/UTX and p300 inhibition may provide therapeutic benefit to patients with T-ALL, two additional manuscripts present preclinical evidence in support of this claim (Ntziachristos et al., 2014; Xia et al., 2019).